Dianthus Therapeutics, Inc. /DE/ Lessee, Operating Lease, Liability, to be Paid
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Lessee, Operating Lease, Liability, to be Paid of $1.55 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue · last filed 2026-08-04
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid $1.55M.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid $1.65M.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid $1.71M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid $1.63M.
| Period end | Lessee, Operating Lease, Liability, to be Paid | Lessee, Operating Lease, Liability, to be Paid as first filed |
|---|---|---|
| 2026-06-30 | $1.55M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.65M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.71M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $1.63M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.70M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.79M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $1.92M 10-K · filed 2025-03-11 | |
| 2024-09-30 | $328.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $434.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $536.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $639.00K 10-K · filed 2024-03-21 | |
| 2023-09-30 | $741.00K 10-Q · filed 2023-11-09 | |
| 2022-12-31 | $904.00K 8-K · filed 2023-12-21 | $39.90M 10-K · filed 2023-03-23 |
| 2022-09-30 | $41.57M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $43.24M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |